Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 16, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in following the milestone moments of our portfolio companies.
Corporate ESG
Polestones and Emirates Nature-WWF Forge Strategic Partnership
Recently, Qiming Venture Partners portfolio company Polestones announced a strategic partnership with Emirates Nature-WWF.
Polestones donated two ROX 01 vehicles to Emirates Nature-WWF, which will help the organization's teams reach remote areas, accelerate field operations, and support the UAE's sustainable development goals.
Major Partnerships
01/
StepFun and Canxing Culture Reach Strategic Partnership
Recently, Canxing Culture and Qiming Venture Partners portfolio company StepFun reached a strategic partnership. The two parties will work together to drive the deep integration of artificial intelligence and the entertainment industry. This collaboration not only marks a powerful alliance in content creation and entertainment marketing, but will also bring more AI + entertainment industry innovations and upgrades.
By integrating StepFun's Step series music foundation models and other leading multimodal technologies, combined with Canxing Culture's professional advantages in the entertainment field, the two parties will deeply apply AI technology under the principle of "complementary strengths and mutual benefit," drive innovation in entertainment, explore how multimodal AI foundation models can empower entertainment projects, and push more creative projects to fruition. They will continuously advance the deep integration of AI and the entertainment industry, creating more diversified and interactive entertainment experiences, and bringing global users a new form of entertainment where technology and creativity intertwine.
02/
Shengshu Technology and Amazon Web Services Marketplace Reach Deep Cooperation
Recently, Qiming Venture Partners portfolio company Shengshu Technology reached deep cooperation with Amazon Web Services Marketplace. Its video foundation model Vidu AI is now officially available on Amazon Web Services Marketplace, bringing more advanced and efficient AI video generation tools to global creators and enterprise users, and accelerating the expansion and commercialization of AI video content creation worldwide.
Since going live, through Amazon Web Services Marketplace, Shengshu Technology has rapidly helped multiple customers accelerate the transformation from technological innovation to commercial application. For example, to help a leading image editing brand expand into the video domain, Shengshu Technology leveraged Amazon Web Services' powerful performance and resources to build customized AI video generation services. This cooperation not only achieved seamless connection from model R&D to commercial deployment, but also validated Shengshu Technology's reliability and flexibility in deploying technology in complex commercial scenarios. More importantly, Shengshu Technology and Amazon Web Services Marketplace have innovatively explored a new "multimodal model + cloud service provider + AI enterprise" tripartite win-win model, providing a replicable practical example for the widespread application of AI technology across industries.
Recently, Shengshu Technology has reached partnerships with multiple industry-leading enterprises. For example, Zhipu AI announced the integration of Shengshu Technology's flagship product Vidu's advanced capabilities in multimodal generation, with its MaaS platform fully connecting to the Vidu video model API; Lark announced a partnership with Shengshu Technology's Vidu, allowing Lark users to directly invoke Vidu through Lark's multidimensional table AI field shortcuts, achieving one-click intelligent video generation from creative concept to finished product; Baidu Search announced at the Baidu Create conference that Vidu has joined the Baidu Search open platform.
03/
Hesai Technology Powers Official Launch of Li Auto L Series Intelligent Refresh Models
Recently, Li Auto officially launched four refreshed intelligent models in its L series. One of the core highlights of this refresh is that the entire L series comes standard with ATL all-weather lidar from Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI), achieving all-weather precision perception with a smaller form factor and stronger detection capabilities.
Compared to Hesai Technology's AT128 equipped on Li Auto's previous-generation product, the Hesai Technology ATL reduces volume by 60% and weight by 60%. The exposed minimum window height is only 25mm, roughly half of the previous design. The best angular resolution reaches 0.08°×0.1°, a 2.5x improvement, with enhanced small-object detection capabilities. During high-speed driving, with optical zoom activated, it can achieve detection range of up to 200 meters within a 30° narrowed field of view, with resolution doubling again, providing more ample reaction time and safety margin for intelligent driving.
04/
Sino Biological and Guangdong Provincial Public Health Research Institute Establish Digital Intelligence Bio-innovation Assessment Joint Laboratory
To promote the translation and application of biotechnology innovation achievements in disease prevention and control, Qiming Venture Partners portfolio company Sino Biological (301047.SZ) and the Guangdong Provincial Public Health Research Institute have established the "Digital Intelligence Bio-innovation Assessment Joint Laboratory."
The joint laboratory will use "digital intelligence" as its connecting thread, focusing on key issues in disease prevention and control and the biopharmaceutical field. Following the signing ceremony, the two parties held in-depth discussions on the joint laboratory's next R&D work plans, communicating on the development of prevention and control products for respiratory, intestinal, and vector-borne infectious diseases.
R&D Progress
01/
MediLink Therapeutics Presents Three Innovative Research Findings at AACR 2025
At the 2025 American Association for Cancer Research (AACR 2025) annual meeting, Qiming Venture Partners portfolio company MediLink Therapeutics presented two latest preclinical datasets and its next-generation ADC dual-toxin platform.
Among them, YL217 is a CDH17-targeting ADC built on MediLink's TMALIN® platform, designed to release its payload in tumor cells and the tumor microenvironment. YL217 demonstrated excellent tumor-killing efficacy and favorable tolerability in both in vitro and in vivo models with high or low CDH17 expression.
YL242 is a non-internalizing ADC targeting soluble VEGF, also built on the TMALIN® platform. It aims to combine anti-angiogenic effects via VEGF targeting with tumor microenvironment-released cytotoxic payload to exert anti-tumor activity. YL242 showed significant dose-dependent tumor-killing effects in tumor xenograft mouse models and good tolerability in non-human primate toxicology studies.
MediLink also developed an innovative dual-payload ADC with a dual mechanism of action combining a topoisomerase I inhibitor and a microtubule inhibitor. This dual-payload toxin conjugated with trastuzumab demonstrated good stability, homogeneity, and precise DAR value.
02/
Jacobio Pharma Publishes SHP2 Inhibitor Combination Study Data in Academic Journal
Recently, Qiming Venture Partners portfolio company Jacobio Pharma (01167.HK) announced that research on its self-developed SHP2 inhibitor sitneprotafib was published in Clinical Cancer Research.
In the article, Jacobio disclosed preclinical in vitro and in vivo data on SHP2 inhibitor combination therapies with PD-1 antibodies and RTK/RAS/MAPK pathway-targeted agents, along with representative patient cases responsive to combination therapy.
The study showed that in combination regimens, JAB-3312 significantly enhanced the anti-tumor activity of KRAS G12C inhibitor glecirasib in both treatment-naïve and resistant models. JAB-3312 combined with MEK inhibitors substantially delayed RTK signal reactivation and enhanced tumor growth inhibition in KRAS-mutant cancer models. JAB-3312 combined with osimertinib demonstrated excellent efficacy in osimertinib-resistant non-small cell lung cancer models. Additionally, JAB-3312 enhanced PD-1 antibody efficacy by promoting an anti-tumor microenvironment.
03/
Shize Biotech's Universal Cell Therapy for ALS Approved for Registration Clinical Trials by Chinese and U.S. Regulators
Recently, Qiming Venture Partners portfolio company Shize Biotech announced that its self-developed "first-in-class" allogeneic universal "off-the-shelf" iPSC-derived subtype neural cell therapy (XS228 injection) received formal approval without any queries from China's National Medical Products Administration (NMPA) for Phase 1 and Phase 2 registration clinical trials. The therapy targets amyotrophic lateral sclerosis (ALS) — one of the "five global incurable diseases" — with Peking University Third Hospital as the lead clinical center and Professor Dongsheng Fan, a top ALS specialist, as the principal investigator.
This follows Shize Biotech's first allogeneic universal "off-the-shelf" iPSC-derived subtype dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease — the world's second most common neurodegenerative disease — which received simultaneous approval without queries from both Chinese and U.S. regulators. XS228 marks Shize Biotech's second universal iPSC-derived cell therapy to be approved for registration clinical trials in both China and the U.S.
04/
AusperBio Announces AHB-137 Phase 2b End-of-Treatment Data
Recently, Qiming Venture Partners portfolio company AusperBio presented end-of-treatment (EOT) data from its Phase 2b clinical trial of AHB-137 in mainland China at the European Association for the Study of the Liver (EASL™) annual meeting, in the form of a late-breaking poster.
AHB-137 is an investigational antisense oligonucleotide (ASO) drug for functional cure of chronic hepatitis B. This presentation highlighted interim data from AHB-137's multicenter, randomized Phase 2b study evaluating its efficacy and safety in HBeAg-negative chronic hepatitis B patients receiving nucleos(t)ide analog (NA) therapy.
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, stated: "AHB-137 demonstrated exciting efficacy data and favorable safety data in the Phase 2b clinical trial, further confirming the excellent clinical outcomes from the Phase 2a trial and underscoring AHB-137's strong potential to become a cornerstone therapy for functional cure of hepatitis B."
05/
Abogen Biosciences' mRNA Therapeutic Cancer Vaccine Clinical Trial Application Approved by FDA
Recently, Qiming Venture Partners portfolio company Abogen Biosciences announced that its self-developed novel mRNA cancer vaccine targeting multiple KRAS mutations received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). The vaccine is indicated for solid tumor patients carrying any of five common KRAS mutations.
This is China's first therapeutic cancer vaccine targeting multiple KRAS mutations, representing major progress in the highly challenging undruggable target space. It marks Abogen Biosciences' emergence as a global leader in tumor immunotherapy innovation with significant international influence.
06/
InferVision's Collaborative Research Published in Top International Journal
Qiming Venture Partners portfolio company InferVision, in collaboration with three top-tier tertiary hospitals — Peking University People's Hospital, Shanghai Pulmonary Hospital, and the Second Xiangya Hospital of Central South University — published its AI 3D reconstruction research in the top international journal Nature Communications. Titled "AI-Driven 3D Reconstruction Technology Improves Lung Surgery Planning," the study comprehensively validated the significant value of InferVision's AI 3D reconstruction system in preoperative anatomical variation identification, surgical approach selection, planning efficiency, and surgeon confidence enhancement.
Results showed that the AI-3D system significantly improved anatomical variation identification accuracy, enabled more precise surgical approach selection, reduced planning time by 25%, and achieved 99% physician satisfaction. These advantages remained consistent across surgeons with varying experience levels. The data demonstrated that InferVision's AI 3D reconstruction system meets core needs in thoracic surgery preoperative planning.
07/
VSA001 NDA Formally Accepted by Chinese Regulator, Partner of Inscinstech
Recently, Qiming Venture Partners portfolio company Inscinstech's partner Vialgen announced that the New Drug Application (NDA) for its self-developed small nucleic acid Class 1 new drug pluxorsen sodium injection (VSA001) was formally accepted by China's National Medical Products Administration (NMPA), becoming China's first breakthrough therapy for familial chylomicronemia syndrome (FCS).
InScience provided critical technical support for the efficient synthesis and purification of VSA001 through its self-developed nucleic acid synthesizer, protein purification system, tangential flow filtration system, and preparative high-pressure liquid chromatography system.
Product Launches
DeepWay Unveils New Heavy-Duty Truck Models
Recently, Qiming Venture Partners portfolio company DeepWay held its spring product launch event, introducing two new energy heavy-duty truck models: the Xingchen II and the Xingtu. Both models feature high-performance, highly reliable self-developed three-electric systems and come standard with L2-level combined assisted driving systems, representing DeepWay's new breakthrough in "intelligent-electric integration" for the heavy-duty commercial vehicle sector.
The Xingchen II delivers multi-dimensional upgrades over its predecessor: an enlarged front air intake area significantly improves heat dissipation to support higher-rate charging; it carries a 505 kWh Hunyuan battery supporting a 900V high-voltage platform, delivering better energy consumption with 20%-80% charging time reduced to 30 minutes, making it suitable for diverse applications including express logistics, cold-chain transport, and general long-haul freight.
Built on the same platform architecture as the Xingchen II, the Xingtu balances performance with cost advantages. Its short wheelbase and high ground clearance are specifically designed for confined spaces and poor road conditions, positioning it as a potentially killer short-wheelbase model for bulk cargo, port, and construction/mixer truck applications in medium- and short-haul transport scenarios.
Technology & Innovation
01/ Multiple Qiming Venture Partners Portfolio Companies Participate in the 21st Shanghai International Automobile Industry Exhibition
The 21st Shanghai International Automobile Industry Exhibition (hereinafter referred to as "2025 Auto Shanghai"), themed "Embrace Innovation, Win-Win Future," recently concluded. Upholding the philosophy of "promoting technological innovation, driving industry collaboration, and deepening market expansion," the exhibition emphasized technological innovation, trend shifts, and market value, welcoming 1.01 million domestic and international visitors. From "internationalization" to "technology-forward," from "industry supporting role" to "global protagonist," from "world's factory" to "innovation source" — 2025 Auto Shanghai once again witnessed a milestone in the globalization of China's auto industry, with China's continued innovation vitality bringing fresh development opportunities to the global automotive industry.
Qiming Venture Partners has invested in multiple high-quality technology companies across the smart vehicle industry chain. During 2025 Auto Shanghai, several Qiming portfolio companies demonstrated their technological capabilities through new product showcases, solutions presentations, and strategic partnership announcements. These included Axera, which is dedicated to building world-leading AI perception and edge computing chips; Zhipu AI, a company with independent innovative algorithms and a leading Chinese cognitive large language model; Polestones, targeting global outdoor enthusiasts as its preferred new energy vehicle brand; Hesai Technology (NASDAQ: HSAI), a global leader in LiDAR R&D and manufacturing; AIBANG, a Chinese independent OTA (Over-the-Air) innovator providing automotive "intelligentization" software technology products and services; and Nasin Technology, a high-tech enterprise focused on core automotive chassis-by-wire technology R&D.
02
WeRide and Uber Expand Strategic Partnership Robotaxi Services to Cover 15 Additional Cities Globally
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) — the world's first publicly listed general autonomous driving company and first Robotaxi company — and Uber Technologies, Inc. (hereinafter referred to as "Uber"), a global leader in mobility and delivery technology, jointly announced an expanded strategic partnership. Over the next five years, they plan to deploy autonomous Robotaxi services in 15 new international cities, including markets in Europe and the Middle East. This partnership upgrade demonstrates how WeRide and Uber are leveraging top-tier autonomous driving technology to lead the future of mobility, accelerating their shared vision of serving global users with autonomous ride-hailing services.
"We are thrilled to take our partnership with Uber to new heights. The intercontinental expansion plan reflects our confidence in both companies' technologies and our shared pursuit of innovative, sustainable transportation solutions," said Tony Han, WeRide's Founder and CEO. "This aligns perfectly with WeRide's grand strategy of enabling global users to access affordable, convenient autonomous mobility services."
03
WeRide W5 Autonomous Logistics Vehicle Receives Guangzhou's First Unmanned Equipment Road Testing License
At the unveiling ceremony for the "Autonomous Driving Test Base and Intelligent Transportation Demonstration Zone" in Guangzhou's Nansha District, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) officially received one of the first unmanned equipment road testing licenses issued by Nansha District, Guangzhou, Guangdong Province. WeRide's autonomous logistics vehicle, the Robovan W5 (hereinafter referred to as "W5 Autonomous Logistics Vehicle"), was approved to conduct road testing activities in Nansha District.
Leveraging its technological leadership and deep operational experience in autonomous driving, WeRide became one of the first enterprises to receive this license, accelerating its progress toward large-scale commercialization of autonomous logistics vehicles.
The WeRide W5 Autonomous Logistics Vehicle is purpose-built for urban freight, serving applications including express delivery, urban distribution, and various point-to-point logistics scenarios. Drawing on nearly six years of public Robotaxi operations, the vehicle employs industry-leading L4 autonomous driving technology to effectively ensure safety and reliability during public road testing and operations.
04
China's First National Standard for Automotive LiDAR, Led by Hesai Technology, Formally Takes Effect
Recently, approved by China's State Administration for Market Regulation and the Standardization Administration of China, the national standard Performance Requirements and Test Methods for Automotive LiDAR (GB/T 45500-2025), with Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) serving as the lead organization and first drafting unit, was formally released and implemented.
The release of this standard not only fills a gap in China's automotive LiDAR technical standards but also lays a solid technical foundation for the ISO international standards led by Hesai Technology. Over the course of more than three years of development, Hesai Technology collaborated with over fifty of China's major LiDAR manufacturers and core OEMs, establishing performance and reliability requirements as well as test methods for automotive LiDAR — giving the standard both industry authority and representativeness.
05
China's First National Standard for Industrial Robot 3D Vision-Guided Systems, Led by Mech-Mind Robotics, Formally Released
Recently, approved by China's State Administration for Market Regulation and the Standardization Administration of China, the national standard Robotics — Three-Dimensional Vision-Guided Systems — General Technical Requirements (GB/T 45501-2025), with Qiming Venture Partners portfolio company Mech-Mind Robotics serving as the lead organization and first drafting unit, was formally released and will take effect on October 1, 2025. This standard's release not only fills a gap in China's industrial robot 3D vision-guided technical standards but also lays a solid foundation for technical standardization in the 3D vision-guided field.
General Technical Requirements for Robotics — 3D Vision Guidance Systems (GB/T 45501-2025) specifies the architecture, basic requirements, functional requirements, performance requirements, and other requirements for 3D vision guidance systems in the industrial robotics field, carrying both industry authority and practical applicability.
06
HyperStrong Debuts at The smarter E Europe
At The smarter E Europe exhibition, Qiming Venture Partners portfolio company HyperStrong (688411.SH) made its appearance under the theme "PIONEERING WITH AI-DRIVEN ENERGY STORAGE," showcasing its latest international energy storage solutions and flagship product portfolio, demonstrating the company's leadership in technological innovation, intelligent management, and globalized services.
At this exhibition, HyperStrong reached strategic partnerships with multiple European collaborators and received the full-series certification for 5MWh AC/DC energy storage prefabricated cabins covering Europe, America, and Australia from TÜV Rheinland — marking a new milestone in the global market compliance and competitiveness of its products. HyperStrong also deepened collaboration with upstream and downstream enterprises across the industry ecosystem to jointly explore sustainable development pathways.
07
Yunji Technology's Composite Polymorphic Robot UP Deployed at Kimberley Hotel Hong Kong
Following the completion of localized elevator adaptation in Hong Kong, Qiming Venture Partners portfolio company Yunji Technology partnered with Kimberley Hotel Hong Kong to deploy the composite polymorphic robot UP for hotel operations. This marks the first application of composite polymorphic robots in Hong Kong's hotel service industry.
The composite polymorphic robot UP deployed at Kimberley Hotel Hong Kong serves as the "limbs" of Yunji Technology's AI agent, capable of coordinated scheduling with the HDOS system that functions as its "brain." The composite polymorphic robot UP features "one machine, multiple capabilities; time-shared multiplexing," enabling end-to-end closed-loop service task completion. By connecting with multiple ecosystem partners and leveraging AIoT interconnectivity, it breaks down information service silos to create an AI agent service space for hotels.
08
Chief Clamp Technology Expert at German Profil Institute Shares Early-Stage R&D Strategy for Gan & Lee Pharmaceuticals' Weekly Insulin
At the 3rd Diabetes and Metabolic Diseases Drug and Device Innovation R&D Conference, Prof. Tim Heise — Chief Scientist, Chairman of the Board, and Co-founder of the German Profil Institute, and advisor to Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) — delivered a special presentation on "Early-Stage R&D Strategy for Insulin: Frontier Technology Construction and Translation." He focused on sharing cutting-edge glucose clamp technology and used Gan & Lee Pharmaceuticals' self-developed GZR4 injection — China's first weekly insulin — as an example to elaborate on the early-stage clinical development approach and strategy for weekly insulin formulations.
GZR4 injection is a Class 1 new drug — a basal insulin weekly formulation self-developed by Gan & Lee Pharmaceuticals — currently undergoing Phase 3 clinical studies. Early clinical research results have demonstrated that GZR4 injection's glucose-lowering effects last approximately one week, with evenly distributed glycemic efficacy throughout the weekly dosing interval, enabling stable glucose control. Additionally, study results suggest that GZR4 injection achieves rapid and effective blood glucose control upon first administration without requiring a supplementary one-time extra dose. Faced with a weekly insulin formulation possessing such unique pharmacological characteristics, Prof. Tim Heise shared his vision for designing targeted glucose clamp clinical trials from multiple perspectives including trial population selection, group design, dose selection, and clamp duration.
09
Jinhua People's Hospital Applies MicroPort EP Pulsed Field Ablation Technology to Complete Paroxysmal Atrial Fibrillation Ablation Surgery
Recently, the cardiac electrophysiology team led by Director Liu Jun at Jinhua People's Hospital in Zhejiang Province successfully completed a paroxysmal atrial fibrillation ablation surgery using pulsed field ablation (PFA) technology from Qiming Venture Partners portfolio company MicroPort EP MedTech (688617.SH) — a first for the hospital.
The surgical team employed MicroPort EP's circular catheter pulsed field ablation solution, with total ablation time of only 36 minutes and immediate bidirectional block verification. The entire procedure — from puncture and mapping electrode placement to anesthesia recovery — took just 54 minutes, confirming Chinese electrophysiology devices' surpassing of traditional radiofrequency surgery in the pulsed field ablation domain.
10/
Baise People's Hospital Applies Tinsight ICE Products to Complete One-Stop Atrial Fibrillation Ablation and Mitral Balloon Valvuloplasty Surgery
Recently, the team led by Prof. Nong Shuxiong at Baise People's Hospital in Guangxi Zhuang Autonomous Region applied Qiming Venture Partners portfolio company Tinsight's intracardiac echocardiography (ICE) products to collaboratively perform a precise ICE-guided one-stop atrial fibrillation ablation and mitral balloon valvuloplasty surgery. Post-surgery, the patient's symptoms of palpitations and chest tightness significantly improved; cardiac ultrasound showed substantial mitigation of mitral stenosis, with no recurrence of atrial fibrillation. ICE technology not only improved surgical success rates but also freed patients from the fear of "open-heart valve replacement."
Tinsight focuses on ultrasound technology innovation in cardiac electrophysiology and structural heart disease, combining imaging, mapping, and ablation energy applications to enable more effective treatment for more cardiac disease patients. To date, Tinsight has obtained registration certificates from the National Medical Products Administration for three intracardiac echocardiography products.
11/
M20 Genomics Contributes to Mapping Alzheimer's Model FFPE Sample Transcriptome Atlas
Recently, Qiming Venture Partners portfolio company M20 Genomics contributed to research published in Nature Communications (impact factor: 14.7) by teams from Southeast University, Yangzhou University, and the Chinese Academy of Sciences Shanghai Institute of Nutrition and Health. By combining cold enzymatic dissociation (CED) with the VITA next-generation single-cell transcriptome platform (snRandom-seq in the paper), the team established the high-fidelity single-nucleus transcriptome technology snCED-seq and performed single-nucleus transcriptome analysis on FFPE samples from Alzheimer's disease (AD) mouse model brain tissue, revealing pathological changes in key neuroglial cell subpopulations and further expanding the application boundaries of FFPE samples in neurodegenerative disease research.
This study systematically validated the feasibility and advantages of combining cold enzymatic dissociation for nucleus extraction with snRandom-seq technology for FFPE samples. Cold enzymatic dissociation significantly improved nucleus extraction efficiency and RNA quality from FFPE samples. Combined with the snRandom-seq platform, the research not only comprehensively depicted AD-related transcriptional features across multiple brain cell types and identified microglial and astrocyte subpopulations closely associated with AD onset, but also discovered a set of disease-susceptibility genes triggering convergent transcriptional responses across different cell types, synergistically driving AD onset and progression — providing important clues for further parsing cellular heterogeneity and transcriptional changes in AD models.
Portfolio Honors
01/ 10+ Qiming Venture Partners Portfolio Companies Named to Star 100: 2025 China AI Industry Trailblazers List
Recently, the Star 100: 2025 China AI Industry Trailblazers List was officially announced. Spanning five sectors — AI chips, large AI models, AI infrastructure, AI applications, and embodied AI — the list captures how artificial intelligence technology has evolved from exploratory research to deep industrial deployment, while showcasing Chinese companies' technical capabilities and growth potential.
Qiming Venture Partners portfolio companies Axera, Biren Technology, Houmo AI, StepFun, Unisound, Zhipu AI, Infinigence AI, Shengshu Technology, Zhihu (NYSE: ZH, 02390.HK), Mech-Mind Robotics, and Galaxy Universal were named to the list.
02/
Multiple Qiming Venture Partners Portfolio Companies Honored at
Touzijia 2025 Robotics Industry Conference · Golden Flint Awards
Recently, the Touzijia 2025 Robotics Industry Conference · Golden Flint Awards were officially announced. The awards aim to recognize enterprises and entrepreneurs in the robotics industry who dare to take on challenges and strive for excellence. The 2025 Robotics Industry Conference · Golden Flint Awards comprise two main categories — enterprise awards and individual awards — covering four major directions in robotics (industrial robots, service robots, core components and system integration, and AI and software ecosystems).
Qiming Venture Partners portfolio companies Meituan (03690.HK), Roborock (688169.SH), Xiaomi (01810.HK), Galaxy Universal, UBTECH (09880.HK), and Yunji Technology were named to the Top 100 Robotics Industry Leaders list; Mech-Mind Robotics, Tashi Zhihang, and Galaxy Universal were named to the Top 60 Most Investment-Worthy Robotics Companies list; Mech-Mind Robotics and Roborock were named to the Top 20 Outstanding Global Expansion Robotics Companies list; Meituan, Xiaomi, and UBTECH were named to the Top 20 Robotics Ecosystem Contributors list; Tashi Zhihang was named to the Top 20 Emerging Robotics Innovators list; Lei Jun, founder, chairman and CEO of Xiaomi, Xing Wang, founder, executive director, CEO and chairman of Meituan, Jing Chang, founder and CEO of Roborock, and He Wang, founder and CTO of Galaxy Universal, were named to the Top 30 Robotics Industry Leaders list.
03/
50+ Qiming Venture Partners Portfolio Companies Named to
2025 Future Healthcare 100 List
Recently, the 2025 Future Healthcare 100 List and company growth report were released. The list and report aim to document the year's industry breakthroughs, reveal growth patterns among listed companies, and identify trends in industrial transformation — providing reference for healthcare enterprises and entrepreneurs. The 2025 Future Healthcare 100 List comprises the main Future Healthcare 100 ranking, the Listed Company Innovation Ranking, and the Future Healthcare 100 Innovation Awards. Qiming Venture Partners and its portfolio companies received multiple honors.
Northmed's intravascular ultrasound system, Cornerstone Robotics' Sentire® laparoscopic surgical robot, Langmu Medical's AqueFish® glaucoma Schlemm's canal drainage stent, and Sage Medical's SA100 ultrasonic high-frequency soft tissue cutting and hemostasis device were named Best Smart Medical Device Technology Innovation Products; Ark Biosciences' ziresovir enteric-coated capsules and CANbridge Pharmaceuticals (01228.HK)'s velaglucerase alfa for injection were named Best Biotechnology Innovation Products; Tuopu Medical's ophthalmic surgical microscope, Sinotau Pharmaceutical's Oweining® florbetaben [18F] injection, and Gan & Lee Pharmaceuticals' bofanglutide were named to the Value Product/Solution list; RuiNing Biotech's Respacio® radiotherapy protective isolation hydrogel was named Most Clinically Notable Product; Pulnovo Medical's PADN interventional product for pulmonary hypertension and Wanzhong Yixin's NGS semiconductor chip gene sequencing instrument were named Most VC-Notable Products.
Heng Liu, co-founder and general manager of BioRay Biopharma, and Xi Yang, co-founder and CEO of Novoprint Biotech, were named Healthcare Entrepreneurs of the Year.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 15, 2025 Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Showcase at the 21st Shanghai International Automobile Industry Exhibition
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage outstanding enterprises in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.